logo
Her 6-Year-Old Son Told Her He Wanted to Die. So She Built an AI Company to Save Him

Her 6-Year-Old Son Told Her He Wanted to Die. So She Built an AI Company to Save Him

Gizmodo17 hours ago
The burgeoning world of AI-powered mental health support is a minefield. From chatbots giving dangerously incorrect medical advice to AI companions encouraging self-harm, the headlines are filled with cautionary tales.
High-profile apps like Character.AI and Replika have faced backlash for harmful and inappropriate responses, and academic studies have raised alarms.
Two recent studies from Stanford University and Cornell University found that AI chatbots often stigmatize conditions such as alcohol dependence and schizophrenia, respond 'inappropriately' to certain common and 'encourage clients' delusional thinking.' They warned about the risk of over-reliance on AI without human oversight.
But against that backdrop, Hafeezah Muhammad, a Black woman, is building something different. And she's doing it for reasons that are painfully personal.
'In October of 2020, my son, who was six, came to me and told me that he wanted to kill himself,' she recounts, her voice still carrying the weight of that moment. 'My heart broke. I didn't see it coming.'
At the time, she was an executive at a national mental health company, someone who knew the system inside and out. Yet, she still couldn't get her son, who has a disability and is on Medicaid, into care.
'Only 30% or less of providers even accept Medicaid,' she explains. 'More than 50% of kids in the U.S. now come from multicultural households, and there weren't solutions for us.'
She says she was terrified, embarrassed and worried about the stigma of a child struggling. So she built the thing she couldn't find.
Today, Muhammad is the founder and CEO of Backpack Healthcare, a Maryland-based provider that has served more than 4,000 pediatric patients, most of them on Medicaid. It's a company staking its future the radical idea that technology can support mental health without replacing the human touch.
On paper, Backpack sounds like many other telehealth startups. In reality, its approach to AI is deliberately pragmatic, focusing on 'boring' but impactful applications that empower human therapists.
An algorithm pairs kids with the best possible therapist on the first try (91% of patients stick with their first match). AI also drafts treatment plans and session notes, giving clinicians back hours they used to lose to paperwork.
'Our providers were spending more than 20 hours a week on administrative tasks,' Muhammad explains. 'But they are the editors.'
This human-in-the-loop approach is central to Backpack's philosophy.
The most critical differentiator for Backpack lies in its robust ethical guardrails. Its 24/7 AI care companion is represented by 'Zipp,' a friendly cartoon character. It's a deliberate choice to avoid the dangerous 'illusion of empathy' seen in other chatbots.
'We wanted to make it clear this is a tool, not a human,' Muhammad says.
Investor Nans Rivat of Pace Healthcare Capital calls this the trap of 'LLM empathy,' where users 'forget that you're talking to a tool at the end of the day.' He points to cases like Character.AI, where a lack of these guardrails led to 'tragic' outcomes.
Muhammad is also adamant about data privacy. She explains that individual patient data is never shared without explicit, signed consent. However, the company does use aggregated, anonymized data to report on trends, like how quickly a group of patients was scheduled for care, to its partners.
More importantly, Backpack uses its internal data to improve clinical outcomes. By tracking metrics like anxiety or depression levels, the system can flag a patient who might need a higher level of care, ensuring the technology serves to get kids better, faster.
Crucially, Backpack's system also includes an immediate crisis detection protocol. If a child types a phrase indicating suicidal ideation, the chatbot instantly replies with crisis hotline numbers and instructions to call 911. Simultaneously, an 'immediate distress message' is sent to Backpack's human crisis response team, who reach out directly to the family.
'We're not trying to replace a therapist,' Rivat says. 'We're adding a tool that didn't exist before, with safety built in.'
Beyond its ethical tech, Backpack is also tackling the national therapist shortage. In many cases, therapists, unlike doctors, traditionally have to pay out of pocket for the expensive supervision hours required to get licensed.
To combat this, Backpack launched its own two-year, paid residency program that covers those costs, creating a pipeline of dedicated, well-trained therapists. More than 500 people apply each year, and the program boasts an impressive 75% retention rate.
In 2021, then-U.S. Surgeon General Dr. Vivek H. Murthy has called mental health 'the defining public health issue of our time' while referring at the time to the mental health crisis plaguing young people.
Muhammad doesn't dodge the criticism that AI could make things worse.
'Either someone else will build this tech without the right guardrails, or I can, as a mom, make sure it's done right,' she says.
Her son is now 11, thriving, and serves as Backpack's 'Chief Child Innovator.'
'If we do our job right, they don't need us forever,' Muhammad says. 'We give them the tools now, so they grow into resilient adults. It's like teaching them to ride a bike. You learn it once, and it becomes part of who you are.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Yahoo

time29 minutes ago

  • Yahoo

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs. 'In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,' said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. 'Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD — we can achieve substantial clinical program advancements.' Highlights from Q2 2025 Durable Complete Remission in Metastatic Testicular Cancer: Nature's Oncogene publication of a landmark case of a patient with treatment-refractory metastatic testicular cancer who achieved a durable complete remission following a single infusion of agenT-797 (allo-INKTs) in combination with checkpoint blockade. The patient remains disease-free more than two years post-treatment. Strengthened Balance Sheet: Increased cash reserves extending runway beyond mid-2026 to advance clinical programs. Department of Defense STTR Grant Awarded for GvHD: Competitive DOD STTR grant awarded to advance development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment; program launched. NEW Clinical Grant Awarded for GvHD: Additional clinical competitive grant awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in 2H2025. Progress in Phase 2 Gastric Cancer Study: Phase 2 trial of agenT-797 in second-line gastric cancer anticipated additional clinical readouts in 2025. Peer-Reviewed Review of iNKT Cell Therapy: A Frontiers in Immunology featured MiNK's platform, highlighting iNKT cells' can remodel the tumor microenvironment and overcome therapeutic resistance, showcasing CAR-iNKTs, such as MiNK-215 as a next-generation solution for solid tumors. Financial Highlights Cash Position: MiNK ended Q2 2025 with approximately $1.6 million in cash and cash equivalents and subsequently raised $13 million through equity sales, providing expected runway into mid-2026. Net Loss: Net loss for Q2 2025 was $4.2 million, or $1.06 per share, compared to $2.7 million, or $0.73 per share for Q2 2024. For the first half of 2025, net loss was $7 million, or $1.76 per share compared to $6.5 million or $1.82 per share for the first half of 2024. Current period results reflect ongoing activity supporting our agent-797 programs and non-cash expenses including the impact of repricing of certain equity awards. Summary Consolidated Financial Information Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) June 30, 2025 Cash and cash equivalents $ 1,682 Cash raised since quarter end 13,012 Other Financial Information (in thousands) (unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Cash used in operations $ 1,569 $ 2,291 $ 2,910 $ 4,833 Non-cash expenses 1,501 491 2,336 1,141 Net loss 4,237 2,702 7,004 6,515 Net loss per share 1.06 0.73 1.76 1.82 Conference Call and Webcast Information MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET. To access the live call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (International) and reference conference ID 1149380. A live webcast and replay will be available in the Events & Presentations section of MiNK's investor website at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370 | investor@ Contact781-674-4422 | communications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Yahoo

time34 minutes ago

  • Yahoo

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company's balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic reactions, including anaphylaxis WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive' or the 'Company'), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ('RTW'), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions. 'This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling us to successfully bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need,' said Dan Barber, Chief Executive Officer of Aquestive. 'We continue to believe Anaphylm, potentially the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, can transform how patients carry and access their rescue medication. We are excited to partner with RTW to bring this important medication to patients, if approved by the FDA.' 'We are excited to support Aquestive, and today's investment reflects our belief in the commercial prospects of Anaphylm as a rescue treatment for patients experiencing a severe allergic reaction, including anaphylaxis,' said Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP. 'We remain committed to helping life science companies bring meaningful innovations, like Anaphylm, to patients, caregivers, and healthcare providers.' The commercial launch financing will become available upon approval of Anaphylm by the FDA, and satisfaction of certain refinancing and other customary conditions related to the Company's existing debt. Under the terms of the agreement, RTW will receive a tiered single digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions (including anaphylaxis), subject to a cap. Cantor Fitzgerald & Co acted as exclusive financial advisor to Aquestive on the royalty financing. About Anaphylm™ (epinephrine) Sublingual FilmAnaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate. About Aquestive TherapeuticsAquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions, including alopecia areata. For more information, visit and follow us on LinkedIn. About RTW Investments, LPRTW Investments, LP is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building and supporting the companies and/or academics developing them. For further information about RTW, please visit Forward-Looking StatementCertain statements in this press release include 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'estimate,' 'intend,' 'may,' 'will,' or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA; the expected plans for regulatory approval and commercialization of Anaphylm in markets outside of the United States, if approved by the applicable regulatory authorities; the potential for Anaphylm to be the first and only orally delivered epinephrine product and its ability change the standard of care; the advancement of the Company's product candidate AQST-108 through clinical development and approval by the FDA for possible various dermatology conditions including alopecia areata; the potential benefits our products and product candidates could bring to patients; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm and AQST-108; risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including with respect to the approval of our filed NDA for Anaphylm, or the failure to receive FDA approval at all for any of our product candidates, including Anaphylm and AQST-108; risk of the Company's ability to generate sufficient clinical data for approval of our product candidates, including with respect to our pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm; risk of the Company's ability to address the FDA's comments on the Company's clinical trials and other concerns identified in the FDA's Type C meeting minutes and filing review letter for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk that the FDA may require that an Advisory Committee be required for the approval of Anaphylm and that the Company is able to address any concerns raised by such Advisory Committee or the FDA after review of the advice from the Advisory Committee; risk of delays in advancement of the regulatory approval process outside the U.S. of our product candidates, including Anaphylm in Canada and the European Union; risk of the success of any competing products, including generics; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm and AQST-108, should these product candidates be approved by the FDA, Health Canada and EMA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in and outside of the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, Health Canada and EMA, and for our licensed products in the U.S. and abroad; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office (USPTO); risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions; risks related to uncertainties about U.S. government initiatives and their impact on our business, including imposition of tariffs and other trade restrictions; and other unusual items; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners. Investor Contact:Brian Korbastr in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy' Rating With $342 PT
Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy' Rating With $342 PT

Yahoo

timean hour ago

  • Yahoo

Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy' Rating With $342 PT

With a low price-to-earnings multiple and a significant presence in Seth Klarman's investment portfolio, Elevance Health, Inc. (NYSE:ELV) earns a spot on our list of the 12 Cheap Value Stocks to Buy Now According to Seth Klarman. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. On July 17, 2025, Elevance Health, Inc. (NYSE:ELV) released its Q2 2025 results. The company posted adjusted EPS of $8.84, slightly missing expectations of $8.91. Increased medical cost trends in ACA, along with slower Medicaid rate recovery softening margins. Yet, the higher premium yields and acquisitions resulted in a $49.4 billion revenue, an increase of 14% YoY. Meanwhile, the company's operating cash flow reached $2.1 billion. Declines in Medicaid and ACA enrollment resulted in a decrease in the Membership segment, taking it to 45.6 million. Looking ahead, Elevance Health, Inc. (NYSE:ELV) reduced its full-year EPS guidance to $30, driven by cost pressures. However, it reaffirmed its strategies to stabilize margins with disciplined pricing, AI-enabled care management, and Carelon's expanding value-based and pharmacy services. Despite the reduction in 2025 guidance, Mizuho maintained its 'Buy' rating on Elevance Health, Inc. (NYSE:ELV) with a $342 price target. The analyst's optimism is driven by the company's growth potential in Carelon and strong execution in Medicare Advantage. Elevance Health, Inc. (NYSE:ELV) is a health insurance provider, offering integrated medical, pharmacy, and care delivery solutions. It is included in our list of cheap value stocks to buy. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store